Industry news
AstraZeneca enters agreement with Perrigo
AstraZeneca has announced that it has entered into an agreement with Perrigo Company plc for the divestment of US rights to Entocort (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn�s disease, an area of medicine outside AstraZeneca�s strategic focus.